Who Generates Higher Gross Profit? Pfizer Inc. or Jazz Pharmaceuticals plc

A Decade of Gross Profit: Pfizer Inc. vs. Jazz Pharmaceuticals plc

In the competitive landscape of pharmaceuticals, gross profit is a key indicator of a company's financial health and market position. Over the past decade, Pfizer Inc. has consistently outperformed Jazz Pharmaceuticals plc in terms of gross profit. From 2014 to 2023, Pfizer's gross profit averaged around $42 billion annually, peaking in 2022 with a staggering $66 billion. In contrast, Jazz Pharmaceuticals, while showing steady growth, averaged approximately $2 billion annually, reaching its highest in 2023 with $3.4 billion.

Pfizer's dominance is evident, with its gross profit being nearly 20 times that of Jazz Pharmaceuticals in most years. However, Jazz's growth trajectory is noteworthy, with a 222% increase from 2014 to 2023. This data highlights the scale and financial prowess of Pfizer, while also showcasing Jazz's impressive growth in a highly competitive industry.